Experience with intraarterial infusion of styrene maleic acid neocarzinostatin (SMANCS)-Lipiodol in pancreatic cancer

A 54 year-aid man was admitted to our hospital and diagnosed with inoperabl e cancer in the body and tail of the pancreas; The spleen was embolized at its hilum with a coil to infuse an anti-tumor agent selectively into the pa ncreatic parenchyma and transcatheter intraarterial infusion (TAI) of styre ne maleic acid neocarzinostatin (SMANCS)-Lipiodol, 3mg, was performed. The computed tomography (CT) scan taken immediately after TAI revealed the inco rporation of SMANCS-Lipiodol into the site of the pancreatic tail. At 2 wee ks, a small amount of SMANCS-Lipiodol remained and clearness of the tumor m argin was lacking in the pancreatic tail, but no remarkable change was note d in the body. As for the laboratory data, pancreatic enzyme level was not elevated immediately after TAI. At 2 weeks, tumor markers showed improvemen t in CEA (3.9-->2.6ng/ml) and Elastase 1 (370-->230ng/ml), but little chang e was seen in CA 19-9 (1600U/ml: no change) and DUPAN-2 (730-->740U/ml). In pancreatic cancer, SMANCS-Lipiodol. could be infused from the splenic arte ry into the pancreatic parenchyma by the splenic arterial embolization.